We are excited to bring you a series of 2 CPD accredited webinars designed to help Healthcare Professionals (HCPs) better manage and prevent Heart Failure in Type 2 Diabetes. This series includes learning resources to complement each webinar: an expert video and 2 podcasts will be made available. Please see the full details below for each of the training webinars.
Webinar #1 – Managing Heart Failure in your patient with diabetes
Mon 7 Dec- 7pm to 8pm
Any delay in the initiation of recommended treatment can have significant impact on patient outcomes. This session will explore the relationship between HF and diabetes. It will review the management of HF and the current evidence supporting the potential role of SGLT2 inhibitors in improving HF outcomes. Drs. David Strain, Marc Evans, Naresh Kanumilli, and Jim Moore will discuss how the new SGLT2 inhibitor evidence is transforming the type 2 diabetes management algorithms.
Speakers: Dr David Strain Clinical Senior Lecturer, Dr Marc Evans Consultant Diabetologist, Dr Naresh Kanumilli Community Diabetes Consultant and Dr Jim Moore GPwSI Cardiology
- Review the prevalence and consequences of heart failure in type 2 diabetes
- Manage a patient with diabetes and heart failure according to the current guidelines
- Apply the latest evidence and guideline recommendations on antihyperglycemic selection to patients with or at risk of heart failure seen in practice
Webinar #2 – Managing CV and HF risk in type 2 diabetes: Beyond glycaemic control
Mon 14 Dec - 7pm to 8pm
Although the hyperglycaemia is commonly the focus in diabetes management, cardiovascular disease complications are the primary cause of death of people with diabetes. Increasing evidence has provided healthcare professionals with options to reduce the risk of cardiovascular disease in type 2 diabetes. This 30-minute session will explore the management strategies to improve glycaemic control and reduce cardiovascular risk.
Speakers: Dr Marc Evans Consultant Diabetologist, Dr Naresh Kanumilli Community Diabetes Consultant, Dr Jim Moore GPwSI Cardiology and Dr. Gethin Ellis Consultant in Cardiology
- Determine the short-term and long-term cardiovascular risk in a patient with type 2 diabetes
- Review the strategies that have been shown to be effective for primary prevention of cardiovascular disease in type 2 diabetes
- Discuss strategies to reduce cardiovascular risk and diabetes during times of limited resources
Strategies for managing at-risk patients with limited access
Heart failure is a common complication in patients with type 2 diabetes. This session will review the incidence and strategies to identify and prevent heart failure. The treatment of heart failure in diabetes will be reviewed. This will include new evidence and guideline recommendations for the management of heart failure in type 2 diabetes.
Class or Drug Effect? – Translating the SGLT2i Evidence
There have been a significant number of trials published on SGLT2 inhibitors in the last several years. A common question from healthcare professionals is if the benefits of these agents are drug-specific or a class effect. Professor John Wilding will provide healthcare professionals with a quick update on the similarities and differences between the SGLT2 inhibitors.
Demystifying the Cardiovascular Evidence with Antihyperglycaemic Agents
The Food and Drug Administration (FDA) in the United States required all new antihyperglycaemic agents to undergo cardiovascular outcome trials prior to approval. This has led to a large number of cardiovascular outcome trials being published. Each of these trials had unique patient criteria and different outcomes. Professor John Wilding and Dr. Naresh Kanumilli will provide healthcare professionals with a quick update on these key trials and how it can impact type 2 diabetes management.